Synthetic organic

Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays &gt: 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50&gt:10 μM).

Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays &gt: 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50&gt:10 μM).

Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays &gt: 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50&gt:10 μM).

Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays &gt: 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50&gt:10 μM).

Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays &gt: 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50&gt:10 μM).

BIC1.

BIC1.

InformationBictegravir (GS-9883) is a novel, potent, once-daily, unboosted inhibitor ofHIV-1 integrase.TargetsHIV-1 integraseIn vitroBictegravir exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T

InformationBictegravir (GS-9883) is a novel, potent, once-daily, unboosted inhibitor ofHIV-1 integrase.TargetsHIV-1 integraseIn vitroBictegravir exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T

InformationBictegravir (GS-9883) is a novel, potent, once-daily, unboosted inhibitor ofHIV-1 integrase.TargetsHIV-1 integraseIn vitroBictegravir exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T

InformationBIIB068 is a potent, selective, reversible and orally active inhibitor of BTK with IC50 of 1 nM and Kd of 0.3 nM, respectively.

BIIB021 is an orally available, fully synthetic small-molecule inhibitor of HSP90 with Ki and EC50 of 1.7 nM and 38 nM, respectively.A selective large conductance calcium activated potassium channel activator.